Lyra Therapeutics Inc (NASDAQ:LYRA) price on Friday, January 17, rose 1.87% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $0.19.
A look at the stock’s price movement, the close in the last trading session was $0.19, moving within a range at $0.187 and $0.1928. The beta value (5-Year monthly) was -0.036. Turning to its 52-week performance, $6.79 and $0.16 were the 52-week high and 52-week low respectively. Overall, LYRA moved 2.69% over the past month.
Lyra Therapeutics Inc’s market cap currently stands at around $12.48 million, with investors looking forward to this quarter’s earnings report slated for in February.
The average forecast suggests up to a 41.10% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 1.52M, representing a -2.21% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that LYRA is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 2 recommend LYRA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
LYRA’s current price about -1.60% and -6.26% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 46.18, while 7-day volatility ratio is 5.57% and 10.76% in the 30-day chart. Further, Lyra Therapeutics Inc (LYRA) has a beta value of -0.12, and an average true range (ATR) of 0.02. Analysts have given the company’s stock an average 52-week price target of $0.5, forecast between a low of $0.5 and high of $0.5. Looking at the price targets, the low is -163.16% off current price level while to achieve the yearly target high, price needs to move -163.16%. Nonetheless, investors will most likely welcome a -163.16% jump to $0.5 which is the analysts’ median price.
If we refocus on Lyra Therapeutics Inc (NASDAQ:LYRA), historical trading data shows that trading volumes averaged 1.72 over the past 10 days and 2.05 million over the past 3 months. The company’s latest data on shares outstanding shows there are 65.46 million shares.
The 18.16% of Lyra Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 46.45% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.1 million on 2024-12-31, giving us a short ratio of 1.24. The data shows that as of 2024-12-31 short interest in Lyra Therapeutics Inc (LYRA) stood at 401.0 of shares outstanding, with shares short falling to 2.2 million registered in 2024-11-29. Current price change has pushed the stock -7.66% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the LYRA stock continues to rise going into the next quarter.
